Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    An Enquiry

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Ozenoxacin

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,640Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Biofrontera Sells Xepi Cream License To Pelthos For Up To $10M
    Biofrontera Sells Xepi Cream License To Pelthos For Up To $10M

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183608/0/en/Biofrontera-Inc-announces-sale-of-license-to-Xepi-Antibiotic-Cream-to-Pelthos-Therapeutics-Inc-for-up-to-10M.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Pelthos Pharma Acquires Xepi Cream, Announces $18M Financing
    Pelthos Pharma Acquires Xepi Cream, Announces $18M Financing

    07 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/07/3183602/0/en/Pelthos-Therapeutics-Acquires-Xepi-ozenoxacin-Cream-1-and-Announces-18-Million-Private-Convertible-Notes-Financing.html

    GLOBENEWSWIRE
    07 Nov 2025
    Share Share
    Luqa Pharmaceuticals and Ferrer Internacional S.A. announce that they have entered into an exclusive agreement to develop and commercialize OZENOXACIN for the treatment of impetigo in China
    Luqa Pharmaceuticals and Ferrer Internacional S.A. announce that they have entered into an exclusive agreement to develop and commercialize OZENOXACIN for the treatment of impetigo in China

    22 Apr 2019

    // PRESS RELEASE

    https://www.ferrer.com/es/node/71

    PRESS RELEASE
    22 Apr 2019
    Share Share